
Simon J Davies

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/60948/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Outcome measures for technique survival reported in peritoneal dialysis: A systematic review. Peritoneal Dialysis International, 2022, 42, 279-287.	2.3	9
2	How do patients and their family members experience the transition from peritoneal dialysis to incentre haemodialysis? A multisite qualitative study in England and Australia. Peritoneal Dialysis International, 2022, 42, 297-304.	2.3	3
3	Assisted peritoneal dialysis performed by caregivers and its association with patient outcomes. Peritoneal Dialysis International, 2022, 42, 602-614.	2.3	7
4	Mortality Trends After Transfer From Peritoneal Dialysis to Hemodialysis. Kidney International Reports, 2022, 7, 1062-1073.	0.8	12
5	Spiritual wellâ€being and its relationship with patient characteristics and other patientâ€reported outcomes in peritoneal dialysis patients: Findings from the PDOPPS. Nephrology, 2022, 27, 621-631.	1.6	4
6	Variation in Peritoneal Dialysis Time on Therapy by Country. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 861-871.	4.5	14
7	Intervening to eliminate the centre-effect variation in home dialysis use: protocol for Inter-CEPt—a sequential mixed-methods study designing an intervention bundle. BMJ Open, 2022, 12, e060922.	1.9	2
8	The osmo-metabolic approach: a novel and tantalizing glucose-sparing strategy in peritoneal dialysis. Journal of Nephrology, 2021, 34, 503-519.	2.0	17
9	Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis—International Results from PDOPPS. Kidney International Reports, 2021, 6, 313-324.	0.8	29
10	ISPD recommendations for the evaluation of peritoneal membrane dysfunction in adults: Classification, measurement, interpretation and rationale for intervention. Peritoneal Dialysis International, 2021, 41, 352-372.	2.3	42
11	Implementation of PDOPPS in a middle-income country: Early lessons from Thailand. Peritoneal Dialysis International, 2021, , 089686082199395.	2.3	10
12	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. Kidney International, 2021, 100, 1101-1111.	5.2	13
13	Expanding Utilization of Home Dialysis: An Action Agenda From the First International Home Dialysis Roundtable. Kidney Medicine, 2021, 3, 635-643.	2.0	22
14	Renal staffs' understanding of patients' experiences of transition from peritoneal dialysis to in-centre haemodialysis and their views on service improvement: A multi-site qualitative study in England and Australia. PLoS ONE, 2021, 16, e0254931.	2.5	2
15	Barriers and opportunities to increase PD incidence and prevalence: Lessons from a European Survey. Peritoneal Dialysis International, 2021, 41, 089686082110349.	2.3	3
16	Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis. Trends in Endocrinology and Metabolism, 2021, 32, 721-730.	7.1	27
17	Challenges of access to kidney care for children in low-resource settings. Nature Reviews Nephrology, 2021, 17, 33-45.	9.6	28
18	Assisted peritoneal dialysis across Europe: Practice variation and factors associated with availability. Peritoneal Dialysis International, 2021, 41, 533-541.	2.3	16

#	Article	IF	CITATIONS
19	Understand the difference between clinical measured ultrafiltrationand real ultrafiltration in peritoneal dialysis. BMC Nephrology, 2021, 22, 382.	1.8	0
20	Providing care for patients with kidney failure over the next decade. Kidney International, 2020, 98, 1062-1063.	5.2	1
21	Strategic plan for integrated care of patients with kidney failure. Kidney International, 2020, 98, S117-S134.	5.2	17
22	The Elusive Promise of Bioimpedance in Fluid Management of Patients Undergoing Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 597-599.	4.5	14
23	Impact of the implementation of an assisted peritoneal dialysis service on peritoneal dialysis initiation. Nephrology Dialysis Transplantation, 2020, 35, 1595-1601.	0.7	20
24	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 861-876.	5.2	126
25	Supportive care for end-stage kidney disease: an integral part of kidney services across a range of income settings around the world. Kidney International Supplements, 2020, 10, e86-e94.	14.2	36
26	International Society for Peritoneal Dialysis practice recommendations: Prescribing high-quality goal-directed peritoneal dialysis. Peritoneal Dialysis International, 2020, 40, 244-253.	2.3	159
27	Accuracy of the estimation of <i>V</i> and the implications this has when applying <i>K</i> _t / <i>V</i> V _{urea} for measuring dialysis dose in peritoneal dialysis. Peritoneal Dialysis International, 2020, 40, 261-269.	2.3	9
28	International comparison of peritoneal dialysis prescriptions from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Peritoneal Dialysis International, 2020, 40, 310-319.	2.3	27
29	Incremental peritoneal dialysis. Peritoneal Dialysis International, 2020, 40, 320-326.	2.3	50
30	Volume management as a key dimension of a high-quality PD prescription. Peritoneal Dialysis International, 2020, 40, 282-292.	2.3	23
31	Patients' experiences of transitioning between different renal replacement therapy modalities: A qualitative study. Peritoneal Dialysis International, 2020, 40, 548-555.	2.3	9
32	The second Global Kidney Health Summit outputs: developing a strategic plan to increase access to integrated end-stage kidney disease care worldwide. Kidney International Supplements, 2020, 10, e1-e2.	14.2	8
33	The role of kidney transplantation as a component of integrated care for chronic kidney disease. Kidney International Supplements, 2020, 10, e78-e85.	14.2	13
34	Raising the standard of trial registration, conduct, and reporting. Peritoneal Dialysis International, 2020, 40, 112-114.	2.3	1
35	Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized) Tj ETQq1 1 0.78 Diseases, 2020, 75, 404-412.	34314 rgB7 1.9	[Overlock] 92
36	Enriching the Evidence Base for Icodextrin. American Journal of Kidney Diseases, 2020, 75, 821-823.	1.9	1

#	Article	IF	CITATIONS
37	International Anemia Prevalence and Management in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2019, 39, 539-546.	2.3	24
38	Peritoneal Ultrafiltration for Heart Failure: Lessons from a Randomized Controlled Trial. Peritoneal Dialysis International, 2019, 39, 486-489.	2.3	12
39	Reaching consensus on the important outcomes for peritoneal dialysis patients. Kidney International, 2019, 96, 545-546.	5.2	2
40	Transition between Different Renal Replacement Modalities: Gaps in Knowledge and Care—the Integrated Research Initiative. Peritoneal Dialysis International, 2019, 39, 4-12.	2.3	24
41	Peritoneal Protein Clearance Is a Function of Local Inflammation and Membrane Area Whereas Systemic Inflammation and Comorbidity Predict Survival of Incident Peritoneal Dialysis Patients. Frontiers in Physiology, 2019, 10, 105.	2.8	22
42	Estimating risk of encapsulating peritoneal sclerosis accounting for the competing risk of death. Nephrology Dialysis Transplantation, 2019, 34, 1585-1591.	0.7	13
43	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Clobal Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 37-47.	5.2	235
44	International Variations in Peritoneal Dialysis Utilization and Implications for Practice. American Journal of Kidney Diseases, 2019, 74, 101-110.	1.9	49
45	Local solutions save young lives. Nature Reviews Nephrology, 2019, 15, 127-128.	9.6	0
46	United Kingdom Catheter Study – Protocol Synopsis. Peritoneal Dialysis International, 2018, 38, 113-118.	2.3	3
47	Fluid Assessment in Peritoneal Dialysis—There is Still a Place for Clinical Acumen. Peritoneal Dialysis International, 2018, 38, 81-82.	2.3	0
48	Bioimpedance-defined overhydration predicts survival in end stage kidney failure (ESKF): systematic review and subgroup meta-analysis. Scientific Reports, 2018, 8, 4441.	3.3	80
49	United Kingdom Catheter Study – Protocol Synopsis. Peritoneal Dialysis International, 2018, 38, 113-118.	2.3	5
50	The use of bioimpedance spectroscopy to guide fluid management in patients receiving dialysis. Current Opinion in Nephrology and Hypertension, 2018, 27, 406-412.	2.0	24
51	Does alanyl-glutamine supplementation offer potential to improve peritoneal dialysate biocompatibility?. Kidney International, 2018, 94, 1050-1052.	5.2	1
52	Insights on Peritoneal Dialysis in China. Peritoneal Dialysis International, 2018, 38, 16-18.	2.3	10
53	Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1526-1533.	4.5	34
54	Ethical issues in dialysis therapy. Lancet, The, 2017, 389, 1851-1856.	13.7	42

#	Article	IF	CITATIONS
55	miR-21 Promotes Fibrogenesis in Peritoneal Dialysis. American Journal of Pathology, 2017, 187, 1537-1550.	3.8	30
56	Are Peritoneal Dialysis Center Characteristics a Modifiable Risk Factor to Improve Peritoneal Dialysis Outcomes?. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1032-1034.	4.5	5
57	Response to Koratala et al International Journal of Cardiology, 2017, 234, 109-110.	1.7	0
58	A prospective, proteomics study identified potential biomarkers of encapsulating peritoneal sclerosis in peritoneal effluent. Kidney International, 2017, 92, 988-1002.	5.2	24
59	Rationale and design of BISTRO: a randomized controlled trial to determine whether bioimpedance spectroscopy-guided fluid management maintains residual kidney function in incident haemodialysis patients. BMC Nephrology, 2017, 18, 138.	1.8	17
60	Spinal meningioma: relationship between degree of cord compression and outcome. British Journal of Neurosurgery, 2017, 31, 209-211.	0.8	15
61	Ultrafiltration for acute decompensated cardiac failure: A systematic review and meta-analysis. International Journal of Cardiology, 2017, 228, 122-128.	1.7	17
62	UK Renal Registry 19th Annual Report: Chapter 13 Home Therapies in 2015: National and Centre-specific Analyses. Nephron, 2017, 137, 297-326.	1.8	14
63	The Authors Reply. Kidney International, 2017, 92, 1290.	5.2	Ο
64	Peritoneal Membrane Dysfunction. , 2017, , 451-460.e2.		1
65	SP435VARIATION IN THE TREATMENT AND PREVENTION OF PERITONEAL DIALYSIS RELATED INFECTIONS: PRELIMINARY RESULTS FROM THE PERITONEAL DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (PDOPPS). Nephrology Dialysis Transplantation, 2016, 31, i236-i237.	0.7	0
66	UK National Survey of Practice Patterns of Fluid Volume Management in Haemodialysis Patients: A Need for Evidence. Blood Purification, 2016, 41, 324-331.	1.8	33
67	Technique Failure—Talking a Common Language. Peritoneal Dialysis International, 2016, 36, 583-584.	2.3	2
68	Unraveling the mechanisms ofÂprogressive peritoneal membrane fibrosis. Kidney International, 2016, 89, 1185-1187.	5.2	12
69	The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS): Unifying Efforts to Inform Practice and Improve Global Outcomes in Peritoneal Dialysis. Peritoneal Dialysis International, 2016, 36, 297-307.	2.3	107
70	Writing for Peritoneal Dialysis International. Peritoneal Dialysis International, 2016, 36, 121-121.	2.3	0
71	Normalizing the peritoneal dialysis dose—have we got it right?. Kidney International, 2016, 90, 1162-1163.	5.2	2
72	Patient Acceptability of the Yorkshire Dialysis Decision AID (YODDA) Booklet: A Prospective Non-Randomized Comparison Study across 6 Predialysis Services. Peritoneal Dialysis International, 2016, 36, 374-381.	2.3	73

#	Article	IF	CITATIONS
73	The Current State of Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2016, 27, 3238-3252.	6.1	366
74	Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid Study. Nephrology Dialysis Transplantation, 2016, 31, 480-486.	0.7	47
75	Longitudinal bioimpedance vector plots add little value to fluid management of peritoneal dialysis patients. Kidney International, 2016, 89, 487-497.	5.2	45
76	Heart failure and chronic obstructive pulmonary disease multimorbidity at hospital discharge transition: a study of patient and carer experience. Health Expectations, 2015, 18, 2401-2412.	2.6	27
77	What are the Consequences of Volume Expansion in Chronic Dialysis Patients?. Seminars in Dialysis, 2015, 28, 239-242.	1.3	6
78	The Authors Reply:. Kidney International, 2015, 87, 240.	5.2	0
79	Transition between home dialysis modalities: another piece in the jigsaw of the integrated care pathway. Nephrology Dialysis Transplantation, 2015, 30, 1781-1783.	0.7	4
80	Patients' Perceptions of Information and Education for Renal Replacement Therapy: An Independent Survey by the European Kidney Patients' Federation on Information and Support on Renal Replacement Therapy. PLoS ONE, 2014, 9, e103914.	2.5	59
81	Histological and Clinical Findings in Patients with Post-Transplantation and Classical Encapsulating Peritoneal Sclerosis: A European Multicenter Study. PLoS ONE, 2014, 9, e106511.	2.5	18
82	Breath analysis of ammonia, volatile organic compounds and deuterated water vapor in chronic kidney disease and during dialysis. Bioanalysis, 2014, 6, 843-857.	1.5	65
83	Analgesia dose prescribing and estimated glomerular filtration rate decline: a general practice database linkage cohort study. BMJ Open, 2014, 4, e005581-e005581.	1.9	3
84	Update on the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Peritoneal Dialysis International, 2014, 34, 332-332.	2.3	8
85	Peritoneal Solute Transport and Inflammation. American Journal of Kidney Diseases, 2014, 64, 978-986.	1.9	32
86	Longitudinal Study of Small Solute Transport and Peritoneal Protein Clearance in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 326-334.	4.5	26
87	Extending the role of peritoneal dialysis: can we win hearts and minds?. Nephrology Dialysis Transplantation, 2014, 29, 1648-1654.	0.7	10
88	The role of bioimpedance and biomarkers in helping to aid clinical decision-making of volume assessments in dialysis patients. Kidney International, 2014, 86, 489-496.	5.2	235
89	Interleukin-6 Signaling Drives Fibrosis in Unresolved Inflammation. Immunity, 2014, 40, 40-50.	14.3	297
90	Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Family Practice, 2013, 30, 247-255.	1.9	99

#	Article	IF	CITATIONS
91	Peritoneal dialysis—current status and future challenges. Nature Reviews Nephrology, 2013, 9, 399-408.	9.6	74
92	What has balANZ taught us about balancing ultrafiltration with * membrane preservation?. Nephrology Dialysis Transplantation, 2013, 28, 1971-1974.	0.7	5
93	Independent Effects of Systemic and Peritoneal Inflammation on Peritoneal Dialysis Survival. Journal of the American Society of Nephrology: JASN, 2013, 24, 2071-2080.	6.1	161
94	Towards Standardized Reporting in Studies of Encapsulating Peritoneal Sclerosis. Peritoneal Dialysis International, 2013, 33, 482-486.	2.3	6
95	Hypoalbuminaemia, systemic albumin leak and endothelial dysfunction in peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2012, 27, 4437-4445.	0.7	38
96	Prospective Safety Study of Bardoxolone Methyl in Patients with Type 2 Diabetes Mellitus, End-Stage Renal Disease and Peritoneal Dialysis. Contributions To Nephrology, 2012, 178, 157-163.	1.1	5
97	Proof-of-principle study to detect metabolic changes in peritoneal dialysis effluent in patients who develop encapsulating peritoneal sclerosis. Nephrology Dialysis Transplantation, 2012, 27, 2502-2510.	0.7	23
98	Injection of deuterated water into the pulmonary/alveolar circulation; measurement of HDO in exhaled breath and implications to breath analysis. Journal of Breath Research, 2012, 6, 036005.	3.0	4
99	An update on peritoneal dialysis solutions. Nature Reviews Nephrology, 2012, 8, 224-233.	9.6	82
100	Determinants of Peritoneal Membrane Function Over Time. Seminars in Nephrology, 2011, 31, 172-182.	1.6	65
101	Summary of the 5th Edition of the Renal Association Clinical Practice Guidelines (2009–2012). Nephron Clinical Practice, 2011, 118, c27-c70.	2.3	23
102	l-Carnitine: more than just an alternative to glucose as an osmotic agent for peritoneal dialysis?. Kidney International, 2011, 80, 565-566.	5.2	2
103	Timing of dialysis initiation and choice of dialysis modality. Nature Reviews Nephrology, 2011, 7, 66-68.	9.6	10
104	Article Commentary: Do We Really Know the Meaning of Sodium Removal?. Peritoneal Dialysis International, 2011, 31, 383-386.	2.3	6
105	Peritoneal Dialysis Research in the UK: The Cardiff Contribution. Peritoneal Dialysis International, 2011, 31, 39-42.	2.3	1
106	Getting More Out of Clinical Practice Guidelines. Peritoneal Dialysis International, 2011, 31, 631-635.	2.3	1
107	Renal Association Clinical Practice Guideline on Peritoneal Dialysis. Nephron Clinical Practice, 2011, 118, c287-c310.	2.3	9
108	Dopexamine Has No Additional Benefit in High-Risk Patients Receiving Goal-Directed Fluid Therapy Undergoing Major Abdominal Surgery. Anesthesia and Analgesia, 2011, 112, 130-138.	2.2	32

#	Article	IF	CITATIONS
109	Human Neutrophil Clearance of Bacterial Pathogens Triggers Anti-Microbial γδT Cell Responses in Early Infection. PLoS Pathogens, 2011, 7, e1002040.	4.7	106
110	Permeability of Peritoneal and Glomerular Capillaries: What are the Differences According to Pore Theory?. Peritoneal Dialysis International, 2011, 31, 249-258.	2.3	35
111	PD in the UK: The Past, Present, and Future. Peritoneal Dialysis International, 2011, 31, 34-35.	2.3	8
112	A Collaborative Approach to Understanding EPS: The European Perspective. Peritoneal Dialysis International, 2011, 31, 245-248.	2.3	24
113	Achieving Euvolemia in Peritoneal Dialysis Patients: A Surprisingly Difficult Proposition. Seminars in Dialysis, 2010, 23, 456-461.	1.3	16
114	Plasma Volume, Albumin, and Fluid Status in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1463-1470.	4.5	106
115	Dispersal kinetics of deuterated water in the lungs and airways following mouth inhalation: real-time breath analysis by flowing afterglow mass spectrometry (FA-MS). Journal of Breath Research, 2010, 4, 017109.	3.0	7
116	A new comorbidity index for estimating mortality risk in ESRD. Nature Reviews Nephrology, 2010, 6, 391-393.	9.6	4
117	The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney International, 2010, 78, 611-618.	5.2	91
118	Isoprene levels in the exhaled breath of 200 healthy pupils within the age range 7–18 years studied using SIFT-MS. Journal of Breath Research, 2010, 4, 017101.	3.0	90
119	Understanding the variability in Ultrafiltration Obtained with Icodextrin. Peritoneal Dialysis International, 2009, 29, 407-411.	2.3	5
120	Peritoneal Protein Clearance and not Peritoneal Membrane Transport Status Predicts Survival in a Contemporary Cohort of Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1201-1206.	4.5	85
121	Combining Near-Subject Absolute and Relative Measures of Longitudinal Hydration in Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1791-1798.	4.5	43
122	Long-Term Changes in Solute and Water Transport. Contributions To Nephrology, 2009, 163, 15-21.	1.1	5
123	The effects of low-sodium peritoneal dialysis fluids on blood pressure, thirst and volume status. Nephrology Dialysis Transplantation, 2009, 24, 1609-1617.	0.7	74
124	Effect of change in renal replacement therapy modality on laboratory variables: a cohort study from the UK Renal Registry. Nephrology Dialysis Transplantation, 2009, 24, 2877-2882.	0.7	7
125	Preserving residual renal function in peritoneal dialysis: volume or biocompatibility?. Nephrology Dialysis Transplantation, 2009, 24, 2620-2622.	0.7	43
126	Over-representation of diabetic patients with renal anaemia in the primary care setting. Family Practice, 2009, 26, 180-182.	1.9	1

#	Article	IF	CITATIONS
127	Adequacy of Dialysis and Dietary Advice. , 2009, , 235-250.		1
128	Clinical Outcomes after Failed Renal Transplantation—Does Dialysis Modality Matter?. Seminars in Dialysis, 2008, 21, 239-244.	1.3	26
129	Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange. Nephrology Dialysis Transplantation, 2008, 23, 2982-2988.	0.7	50
130	A non-invasive, on-line deuterium dilution technique for the measurement of total body water in haemodialysis patients. Nephrology Dialysis Transplantation, 2008, 23, 2064-2070.	0.7	25
131	Optimizing automated peritoneal dialysis: increasing nightly dialysate flow vs adding a manual daytime exchange. Nature Clinical Practice Nephrology, 2007, 3, 248-249.	2.0	1
132	Reflections on the Academic Policy Analysis Process and the UK Identity Cards Scheme. Information Society, 2007, 23, 51-58.	2.9	25
133	What have we Learned about PD from Recent Major Clinical Trials?. Peritoneal Dialysis International, 2007, 27, 131-135.	2.3	8
134	Achieving Euvolemia in Peritoneal Dialysis. Peritoneal Dialysis International, 2007, 27, 514-517.	2.3	10
135	EAPOS: what have we learned?. Peritoneal Dialysis International, 2007, 27, 131-5.	2.3	1
136	Overfill or Ultrafiltration? We Need to be Clear. Peritoneal Dialysis International, 2006, 26, 449-451.	2.3	27
137	What is the Link between Poor Ultrafiltration and Increased Mortality in Anuric Patients on Automated Peritoneal Dialysis? Analysis of Data from Eapos. Peritoneal Dialysis International, 2006, 26, 458-465.	2.3	39
138	Exploring new evidence of the clinical benefits of icodextrin solutions. Nephrology Dialysis Transplantation, 2006, 21, ii47-ii50.	0.7	29
139	Peritoneal Dialysis after a Failed Transplant. , 2006, 150, 271-277.		1
140	Overfill or ultrafiltration? We need to be clear. Peritoneal Dialysis International, 2006, 26, 449-51.	2.3	15
141	What is the link between poor ultrafiltration and increased mortality in anuric patients on automated peritoneal dialysis? Analysis of data from EAPOS. Peritoneal Dialysis International, 2006, 26, 458-65.	2.3	20
142	Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescription. Kidney International, 2005, 67, 1609-1615.	5.2	158
143	Getting to Grips with Individual Variation in Membrane Function. Peritoneal Dialysis International, 2005, 25, 35-37.	2.3	2
144	A detailed analysis of sodium removal by peritoneal dialysis: comparison with predictions from the three-pore model of membrane function. Nephrology Dialysis Transplantation, 2005, 20, 1192-1200.	0.7	23

#	Article	IF	CITATIONS
145	Influence of Convection on the Diffusive Transport and Sieving of Water and Small Solutes across the Peritoneal Membrane. Journal of the American Society of Nephrology: JASN, 2005, 16, 437-443.	6.1	19
146	Are PD patients with or without residual renal function qualitatively differentor are they simply at different stages of the continuum of progressive uraemia?. Nephrology Dialysis Transplantation, 2005, 20, 270-272.	0.7	5
147	Peritoneal Dialysis Solutions. , 2005, , 534-552.		1
148	Getting to grips with individual variation in membrane function. Peritoneal Dialysis International, 2005, 25, 35-7.	2.3	4
149	Relationship of Demographic, Dietary, and Clinical Factors to the Hydration Status of Patients on Peritoneal Dialysis. Peritoneal Dialysis International, 2004, 24, 231-239.	2.3	28
150	Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney International, 2004, 66, 2437-2445.	5.2	199
151	Longitudinal measurements of total body water and body composition in healthy volunteers by online breath deuterium measurement and other near-subject methods. International Journal of Body Composition Research, 2004, 2, 99-106.	0.5	5
152	Icodextrin Improves the Fluid Status of Peritoneal Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2003, 14, 2338-2344.	6.1	328
153	Survival of Functionally Anuric Patients on Automated Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2003, 14, 2948-2957.	6.1	353
154	Examine the Individual, Not the Species Nephron Clinical Practice, 2003, 95, c1-c2.	2.3	0
155	Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrology Dialysis Transplantation, 2002, 17, 1085-1092.	0.7	328
156	Integrated Care. Peritoneal Dialysis International, 2001, 21, 269-274.	2.3	51
157	Peritoneal Glucose Exposure and Changes in Membrane Solute Transport with Time on Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2001, 12, 1046-1051.	6.1	341
158	Trace gases in breath of healthy volunteers when fasting and after a protein-calorie meal: a preliminary study. Journal of Applied Physiology, 1999, 87, 1584-1588.	2.5	160
159	Quantification of breath isoprene using the selected ion flow tube mass spectrometric analytical method. , 1999, 13, 1733-1738.		81
160	Quantification of ammonia in human breath by the selected ion flow tube analytical method using H3O+ and O2+ precursor ions. , 1998, 12, 763-766.		74
161	What really happens to people on long-term peritoneal dialysis?. Kidney International, 1998, 54, 2207-2217.	5.2	315
162	Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: Their interrelationship and prediction of survival. American Journal of Kidney Diseases, 1995, 26, 353-361.	1.9	264

#	Article	IF	CITATIONS
163	Glomerular Injury Induced by Hydrogen Peroxide: Modifying Influence of Ace Inhibitors. Free Radical Research Communications, 1992, 17, 271-278.	1.8	5
164	International Icodextrin Use and association with peritoneal membrane function, fluid removal, patient and technique survival. Kidney360, 0, , 10.34067/KID.0006922021.	2.1	4
165	Monitoring residual kidney function in haemodialysis patients using timed urine collections: validation of the use of estimated blood results to calculate GFR. Physiological Measurement, 0, , .	2.1	2